Introduction
============

Familial cylindromatosis is characterized by formation of multiple benign tumours originating from skin ([@b3]). The tumour syndrome is caused by the loss of both *CYLD* alleles. The *CYLD* gene encodes a deubiquitinating enzyme, which removes lysine 48- or lysine 63-linked polyubiquitin chains from target proteins ([@b23]). Depending on the cellular context CYLD has been shown to negatively regulate NF-κB and/or JNK-signalling pathways resulting in suppression of cell proliferation and survival ([@b7]; [@b19]; [@b40]; [@b30]). The mechanism by which CYLD exerts its tumour-suppressor function *in vivo* has been analyzed in CYLD-null mice, which are highly susceptible to chemically induced skin tumours. The increased tumour incidence was attributed to the loss of an inhibitory interaction between CYLD and the proto-oncogene Bcl-3. The association of CYLD with Bcl-3, which results from activation and subsequent perinuclear translocation of the protein, leads to the removal of a lysine 63-linked ubiquitin chain from Bcl-3, which in turn inhibits the nuclear translocation and activity of Bcl-3 ([@b21]). In the absence of CYLD, Bcl-3 is able to translocate into the nucleus where it forms a complex with the NF-κB p50 and p52 isoforms. This results in activation of the cyclin-D1 promoter and increased proliferation and tumour growth ([@b21]). It is not clear, however, how CYLD translocates to the perinuclear region to capture Bcl-3 and whether this is the only mechanism by which CYLD regulates tumour cell proliferation.

In addition to the C-terminal ubiquitin C-terminal hydrolase (UCH) domain, which executes the removal of ubiquitin chains, CYLD contains three cytoskeleton-associated protein-glycine-conserved (CAP-Gly) domains in the N-terminal portion of the protein. The exact function of CAP-Gly domains is not known, but their presence in various microtubule (MT)-binding proteins suggests that they enable binding to MTs ([@b31]; [@b25]; [@b1]). The third CAP-Gly domain (CAP-Gly3) of CYLD has recently been shown to associate directly with the proline-rich sequences of NEMO/IKKγ, a pseudokinase, which together with IKKα and IKKβ triggers TNF-receptor-mediated NF-κB activation ([@b1]). Interestingly, this CAP-Gly domain ([@b34]) differs structurally from the first two CAP-Gly domains (CAP-Gly1 and CAP-Gly2), which have been recently shown to associate directly with tubulin and promote tubulin polymerization ([@b13]). Whether the CAP-Gly domains in CYLD have any additional function besides tubulin binding is not known.

The stability of MTs is accompanied by post-translational modifications of α-tubulin such as acetylation, which usually occurs after MT assembly ([@b44]). The level of α-tubulin acetylation in cells is accurately adjusted by the activities of tubulin acetyltransferases and deacetylases, which catalyze the acetylation and deacetylation of α-tubulin, respectively. Elp3 was identified very recently as α-tubulin acetyltransferase in neuronal cells ([@b10]), while HDAC6 (histone deacetylase-6) and SIRT2 (the Silent Information Regulator Type-2) have been shown to deacetylate α-tubulin ([@b17]; [@b24]).

HDAC6 contains two intact HDAC catalytic domains, which execute deacetylation of α-tubulin ([@b45]; [@b47]; [@b5]), and a ubiquitin-binding zinc-finger domain, which enables binding to ubiquitinated proteins ([@b36]; [@b16]; [@b4]). Even though HDAC6 contains both intrinsic nuclear import and export signals, it is mainly found in the cytoplasm ([@b41]) where it localizes around the nucleus or at the leading edge of migrating cells ([@b17]). HDAC6 has also been shown to have a scaffold role for lymphocyte migration independent of its activity ([@b8]). Furthermore, the activity of HDAC6 promotes cell motility by regulation of membrane ruffle formation, macropinocytosis, and actin remodelling ([@b14]). Besides regulating cell motility, HDAC6 is also involved in the response of cells to various types of stress stimuli ([@b6]; [@b18]; [@b20]), immune synapse organization, and the antigen-specific reorientation of the microtubule organizing center (MTOC) ([@b37]).

In this paper we addressed the role of CYLD and specifically its N-terminal CAP-Gly domains in the regulation of cell proliferation both in primary keratinocytes and malignant melanoma cells. We found that CYLD associates with MTs and colocalizes primarily with acetylated tubulin. Activation of CYLD increases the levels of acetylated α-tubulin by interaction of the N-terminal domain of CYLD with the catalytic site of HDAC6. This interaction inhibits HDAC6-mediated tubulin deacetylation, allowing CYLD to translocate to the perinuclear region. Perinuclear localized CYLD induces a delay in the G~1~/S transition phase of the cell cycle through a Bcl-3-mediated pathway. In addition, CYLD is found in the midbody where it also associates with HDAC6 and regulates the rate of cytokinesis.

Results
=======

Interaction of CYLD with tubulin and MT
---------------------------------------

We have earlier shown that UV or TPA treatment of primary mouse keratinocytes triggers perinuclear accumulation of CYLD, which correlates with its ability to interact with its downstream targets ([@b21]). The present work aimed at understanding whether an MT-dependent mechanism was involved in the translocation of CYLD. To explore this we used primary mouse keratinocytes, primary human melanocytes, and different human malignant melanoma cells. Analysis of subcellular localization of CYLD in primary mouse keratinocytes revealed that TPA treatment caused a robust increase in perinuclear, acetylated α-tubulin ([Figure 1A](#f1){ref-type="fig"}), and a colocalization of CYLD with acetylated MTs ([Figure 1A](#f1){ref-type="fig"}). However, we could observe only partial colocalization of CYLD with tyrosinated α-tubulin in the cytoplasm ([Supplementary Figure S1A](#S1){ref-type="supplementary-material"}). Interestingly, all melanoma cell lines we have tested so far lack detectable CYLD expression ([@b22]). Therefore, we restored CYLD expression in two different malignant melanoma cell lines, MEL and Juso melanoma cells ([@b33]), by lentivirally transducing full-length, EGFP-tagged CYLD cDNA. In melanoma cells EGFP--CYLD was constitutively present in the perinuclear region where it colocalized with acetylated tubulin ([Supplementary Figure S1B](#S1){ref-type="supplementary-material"}, lower panels), while no colocalization with peripheral, tyrosinated α-tubulin could be observed ([Supplementary Figure S1B](#S1){ref-type="supplementary-material"}, upper panels). These results suggest that CYLD colocalizes mainly with acetylated MTs in the perinuclear region, and this localization is constitutive in CYLD-transduced melanoma cells, whereas in primary mouse keratinocytes or primary human melanocytes ([Supplementary Figure S1C](#S1){ref-type="supplementary-material"}) it is induced after TPA treatment or exposure to UV light. A constitutive perinuclear localization of CYLD has also been reported for other tumour cell lines ([@b28]).

Next we investigated whether CYLD, through its CAP-Gly domains, can interact with MTs. Immunoprecipitation of endogenous CYLD in melanocytes revealed an interaction with α-tubulin ([Figure 1B](#f1){ref-type="fig"}). The interaction of CYLD with tubulin was confirmed by reverse immunoprecipitation of α-tubulin and subsequent immunoblotting against CYLD in melanocytes ([Figure 1B](#f1){ref-type="fig"}) and in primary mouse keratinocytes ([Figure 1C](#f1){ref-type="fig"}). As expected, immunoprecipitation of EGFP--CYLD from melanoma cells co-precipitated α-tubulin ([Supplementary Figure S2A](#S1){ref-type="supplementary-material"}). Furthermore, exposure of keratinocytes ([Figure 1C](#f1){ref-type="fig"}) or melanocytes ([Figure 1D](#f1){ref-type="fig"}) to nocodazole, which depolymerises MTs, induced rapid dissociation of CYLD from MTs, suggesting that CYLD associates with polymerised tubulin. In contrast, the association of drug- and cold-resistant, MT-associated protein-4 (MAP4) ([@b43]), and tubulin was unaffected in the presence of nocodazole ([Figure 1C](#f1){ref-type="fig"}). To confirm the association of CYLD with polymerised MTs, we performed MT-co-sedimentation assays using *in vitro* translated CYLD and *in vitro* assembled MTs. The majority of the CYLD protein was found in the heavy pellet fraction indicating that CYLD binds to polymerised MTs ([Figure 1E](#f1){ref-type="fig"}, upper panels). To control the specificity of our assay, we used *in vitro* translated Bax, which does not bind MTs. As expected, Bax was exclusively found in the supernatant fraction both in the presence and absence of MTs ([Figure 1E](#f1){ref-type="fig"}, lower panels).

To identify the interaction site on CYLD for α-tubulin binding, we transfected HeLa cells with cDNAs encoding FLAG-tagged, full-length CYLD or FLAG-tagged, CYLD-deletion mutants ([Supplementary Figure S2B](#S1){ref-type="supplementary-material"}). FLAG pull-down assays confirmed the interaction between CYLD and α-tubulin, and further showed that the first and the second, but neither the third CAP-Gly nor the UCH, domain of CYLD interacted with α-tubulin ([Figure 1F](#f1){ref-type="fig"}). Together these results indicate that CYLD associates preferentially with polymerised tubulin and that the first and second CAP-Gly domains of CYLD mediate the binding to MTs both *in vitro* and *in vivo*.

CYLD induces acetylation of *α*-tubulin and stabilization of MTs
----------------------------------------------------------------

As CYLD associates with MTs and colocalizes specifically with acetylated MTs, we hypothesized that CYLD might directly regulate α-tubulin acetylation to control its own localization. To investigate this we analysed the levels of acetylated tubulin in primary mouse keratinocytes. Both *Cyld*^*+/+*^ and *Cyld*^*−/−*^ keratinocytes contained low levels of acetylated tubulin ([Figure 2A](#f2){ref-type="fig"}). While TPA treatment did not change the total levels of α-tubulin, it increased the levels of acetylated α-tubulin in *Cyld*^*+/+*^ keratinocytes but not in *Cyld*^*−/−*^ keratinocytes. ([Figure 2A](#f2){ref-type="fig"}). This increase was accompanied by enhanced association of CYLD with acetylated α-tubulin ([Figure 2B](#f2){ref-type="fig"}). Importantly, re-expression of CYLD in *Cyld*^*−/−*^ keratinocytes restored the ability of these cells to respond to TPA by increasing the levels of acetylated α-tubulin ([Figure 2C](#f2){ref-type="fig"}). Reconstitution of melanoma cells with EGFP--CYLD induced an almost sixfold increase in the levels of acetylated α-tubulin ([Figure 2D](#f2){ref-type="fig"}). Furthermore, transient transfection of melanoma cells with increasing concentrations of the EGFP--CYLD cDNA showed direct correlation between levels of CYLD expression and acetylated α-tubulin ([Figure 2E and F](#f2){ref-type="fig"}). These results suggest that CYLD increases the level of acetylated α-tubulin in both TPA-stimulated keratinocytes as well as in untreated melanoma cells. To determine whether the increase in α-tubulin acetylation depends on the deubiquitinase activity of CYLD, we transduced melanoma cells with catalytically inactive CYLD (CYLD^C/S^). CYLD^C/S^ increased the acetylation of α-tubulin to the same extent as with full-length, wild-type CYLD ([Figure 2G](#f2){ref-type="fig"}), indicating that the UCH domain of CYLD is not required for α-tubulin acetylation.

To investigate whether the association of CYLD with MTs influences their dynamic properties, we treated melanoma cells with nocodazole and monitored MT re-growth after nocodazole washout. Polymerised MT fibres in CYLD-expressing melanoma cells were evident already 10 min after the washout ([Figure 2H](#f2){ref-type="fig"}) and acetylated α-tubulin after 30 min ([Figure 2I](#f2){ref-type="fig"}). In EGFP-expressing melanoma cells, however, MT fibres were detected only 30 min after nocodazole washout ([Figure 2H](#f2){ref-type="fig"}), and we failed to observe acetylation of α-tubulin even 2 h after nocodazole washout ([Figure 2I](#f2){ref-type="fig"}). This suggests that CYLD regulates the acetylation of tubulin and also influences the polymerization rate of MTs.

Next, we analysed the effect of CYLD on MT depolymerisation by treating EGFP--CYLD- or EGFP-expressing melanoma cells with increasing concentrations of nocodazole and found that in the presence of CYLD, MTs began to partially depolymerise at 5-μM concentrations (with some MT fibres still detectable) ([Supplementary Figure S3A](#S1){ref-type="supplementary-material"}). Total depolymerisation was achieved with 50 μM nocodazole. In sharp contrast, already 1 μM nocodazole induced partial depolymerisation of MT fibres in EGFP-expressing cells and 5 μM nocodazole was sufficient to induce complete depolymerisation ([Supplementary Figure S3A](#S1){ref-type="supplementary-material"}). Furthermore, treatment with 1 μM nocodazole did not change the level of acetylated tubulin in EGFP--CYLD-expressing melanoma cells ([Supplementary Figure S3B](#S1){ref-type="supplementary-material"}), while treatment with 50 μM of nocodazole resulted in almost complete deacetylation of α-tubulin ([Supplementary Figure S3B](#S1){ref-type="supplementary-material"}). These results indicate that CYLD stabilizes the MT network and protects the MT network from nocodazole-induced depolymerisation.

CYLD binding to HDAC6 increases *α*-tubulin acetylation
-------------------------------------------------------

To analyse whether CYLD regulates tubulin acetylation by inhibiting HDAC6, we treated keratinocytes and melanoma cells with different HDAC inhibitors: tubacin, a small-molecule inhibitor of HDAC6; trichostatin-A (TSA), a chemical inhibitor of class-I and II HDACs, including HDAC6; and sodium butyrate, a potent inhibitor of class-I and II HDACs except HDAC6. Sodium butyrate treatment did not affect the levels of acetylated tubulin either in keratinocytes or in melanoma cells ([Figure 3A](#f3){ref-type="fig"} and [Supplementary Figure S3C](#S1){ref-type="supplementary-material"}). In addition, TPA stimulation of *Cyld*^*+/+*^ keratinocytes led to an increase in acetylated α-tubulin levels both in the presence and absence of sodium butyrate ([Figure 3A](#f3){ref-type="fig"}). In contrast, treatment of *Cyld*^*+/+*^ keratinocytes with either TPA or TSA alone increased acetylated α-tubulin levels to a similar extent, while simultaneous treatment with both the compounds failed to induce a synergistic effect ([Figure 3B](#f3){ref-type="fig"}). Moreover, TSA treatment of *Cyld*^*−/−*^ keratinocytes increased the level of acetylated α-tubulin, while TPA treatment had no effect ([Figure 3B](#f3){ref-type="fig"}). A similar effect was observed in keratinocytes treated with tubacin, which is a selective inhibitor for HDAC6 ([Figure 3C](#f3){ref-type="fig"}). Furthermore, TSA or tubacin treatment increased the levels of acetylated α-tubulin in EGFP-expressing melanoma cells ([Figure 3D and E](#f3){ref-type="fig"}), while treatment of EGFP--CYLD-expressing melanoma cells with TSA or tubacin failed to increase the levels of acetylated α-tubulin ([Figure 3D and E](#f3){ref-type="fig"}). Taken together, these findings suggest that CYLD, TSA, and tubacin act within the same pathway to inhibit HDAC6, which results in elevated levels of acetylated α-tubulin.

Next we investigated whether levels of acetylated tubulin regulate the subcellular localization of CYLD. To analyse this, we inhibited HDAC6 in *Cyld*^*+/+*^ keratinocytes using TSA or by downregulating HDAC6 using siRNA. In the absence of TSA, CYLD localized throughout the cytoplasm ([Figure 3F](#f3){ref-type="fig"}), while in the presence of TSA or in HDAC6-depleted cells, the levels of acetylated tubulin increased and CYLD translocated to the perinuclear region where it strongly colocalized with acetylated MTs ([Figure 3F](#f3){ref-type="fig"} and [Supplementary Figure S3D](#S1){ref-type="supplementary-material"}). TPA treatment of HDAC6-depleted cells induced a similar affect as HDAC6 siRNA alone ([Supplementary Figure S3D](#S1){ref-type="supplementary-material"}). In addition, treatment of keratinocytes with TSA caused an increase in the interaction of CYLD with tubulin as compared with that in untreated cells ([Supplementary Figure S3E](#S1){ref-type="supplementary-material"}).

Since CYLD regulates tumour cell proliferation through direct association with Bcl-3, which in turn inhibits the nuclear translocation and activity of Bcl-3 ([@b21]), we investigated whether intact MTs are required for this interaction. As expected, TPA induced interaction of CYLD with Bcl-3, while this interaction ([Figure 3G](#f3){ref-type="fig"}), as well as perinuclear localization of CYLD ([Supplementary Figure S4A](#S1){ref-type="supplementary-material"}), was prevented in the presence of nocodazole. Furthermore, TSA together with TPA, but not in combination with nocodazole, was able to rescue this interaction ([Figure 3G](#f3){ref-type="fig"}). However, TSA treatment or HDAC6 depletion alone did not induce interaction of CYLD with Bcl-3 ([Figure 3G and H](#f3){ref-type="fig"}).These results suggest that inhibition of HDAC6 and subsequent accumulation of acetylated MTs facilitates the translocation of CYLD to the perinuclear region, while binding to Bcl-3 requires both an intact network of acetylated MTs and an additional signal induced by TPA.

Association of CYLD and HDAC6 in the presence of TPA
----------------------------------------------------

To investigate how CYLD regulates HDCA6 function we analysed whether CYLD regulates the expression of HDAC6. Western blot analyses excluded reduced HDAC6 expression as the cause for diminished HDAC6 function in keratinocytes or melanoma cell lines ([Figure 4A](#f4){ref-type="fig"} and [Supplementary Figure S4B](#S1){ref-type="supplementary-material"}). Furthermore, similar levels of HDAC6 were found in nuclear and cytoplasmic extracts from TPA-treated *Cyld*^*+/+*^ and *Cyld*^*−/−*^ keratinocytes, as well as from melanoma cells before and after EGFP--CYLD transduction ([Figure 4A](#f4){ref-type="fig"} and [Supplementary Figure S4B](#S1){ref-type="supplementary-material"}), indicating that CYLD does not interfere with the subcellular distribution of HDAC6. We also analysed SIRT2, another α-tubulin deacetylase, and did not detect SIRT expression in keratinocytes (data not shown), suggesting that HDAC6 is the major α-tubulin deacetylase in keratinocytes.

To analyse whether CYLD directly influences HDAC6 activity, we first performed co-immunoprecipitation and immunofluorescence experiments using primary keratinocytes. We observed both co-precipitation ([Figure 4B](#f4){ref-type="fig"}) and colocalization ([Figure 4C](#f4){ref-type="fig"}) of the proteins after TPA treatment, indicating that they form a protein complex in response to CYLD activation. The interaction between CYLD and HDAC6 was retained in the presence of nocodazole ([Figure 4B](#f4){ref-type="fig"}), indicating that the interaction between CYLD and HDAC6 does not require intact MTs. Similarly, HDAC6 co-precipitated with EGFP--CYLD in melanoma cells, and this interaction was also retained in the presence of nocodazole ([Supplementary Figure S4C](#S1){ref-type="supplementary-material"}). Furthermore, FLAG pull-down assays with a series of *in vitro* translated, FLAG-tagged CYLD-deletion mutants ([Supplementary Figure S2B](#S1){ref-type="supplementary-material"}) showed that the N-terminal region of CYLD (CYLD^1--212^) harboured the ability to interact with purified HDAC6 protein ([Figure 4D](#f4){ref-type="fig"}).

To define which domain(s) in HDAC6 is required for the interaction with CYLD, a series of HA-tagged HDAC6-deletion mutants ([@b46]) were transiently transfected together with full-length, FLAG-tagged CYLD into HeLa cells. FLAG pull-down assays of CYLD demonstrated that the deletion mutants containing the HDAC6 domain DD1 or DD2 interacted with CYLD ([Figure 4E](#f4){ref-type="fig"}). To confirm this interaction we expressed recombinant GST--HDAC6, His--CYLD, and GST alone as control ([Supplementary Figure S5A](#S1){ref-type="supplementary-material"}). HDAC6 co-precipitated with His--CYLD-bound Ni--NTA agarose, indicating association of these two proteins ([Figure 4F](#f4){ref-type="fig"}). Furthermore, GST pull-down assays using the N-terminal region of CYLD (GST--CYLD^1--212^) and the purified form of His-tagged, full-length HDAC6 confirmed an interaction between CYLD and HDAC6 ([Figure 4G](#f4){ref-type="fig"}).

CYLD inhibits HDAC6 activity by binding to its catalytic domains
----------------------------------------------------------------

As it was shown earlier that DD1 and DD2 are critical for the catalytic activity of HDAC6 ([@b45]), we hypothesized that binding of CYLD to these domains leads to HDAC6 inactivation. To test this hypothesis, we performed *in vitro* tubulin deacetylation assays. We incubated endogenous HDAC6 and/or EGFP--CYLD immunoprecipitates from melanoma cells in the absence or presence of TSA together with MAP-enriched polymerised MTs purified from bovine brain. Whereas HDAC6 alone induced deacetylation of α-tubulin, CYLD or TSA treatment could maintain acetylated α-tubulin even in the presence of HDAC6 ([Figure 5A](#f5){ref-type="fig"}). To confirm the specificity of this effect, we transiently transfected COS cells with increasing concentrations of FLAG--CYLD or HA--HDAC6 cDNA. The polymerised MTs were then incubated with CYLD and/or HDAC6 immunoprecipitates after peptide elution. We found a direct correlation between the levels of CYLD and acetylated α-tubulin *in vitro* ([Figure 5B](#f5){ref-type="fig"}). To identify the domain of CYLD responsible for inhibition of HDAC6, we transiently transfected COS cells with different fragments of CYLD ([Supplementary Figure S2B](#S1){ref-type="supplementary-material"}) or HDAC6. The polymerised MTs were then incubated with immunoprecipitates of these fragments together with HDAC6. As expected, only the CYLD^1--212^ fragment, which mediates the association of CYLD with HDAC6 ([Figure 4D](#f4){ref-type="fig"}), was able to inhibit HDAC6 activity and subsequent α-tubulin deacetylation ([Figure 5C](#f5){ref-type="fig"}).

Next we tested whether TPA-mediated CYLD activation inhibits HDAC6 activity by regulating its interaction with tubulin. To this end, we immunoprecipitated HDAC6 from *Cyld*^*+/+*^ and *Cyld*^*−/−*^ keratinocytes and found that TPA treatment, which was found to induce the interaction of CYLD and HDAC6, did not affect the association of HDAC6 with α-tubulin ([Figure 5D](#f5){ref-type="fig"}). Similarly, EGFP--CYLD did not affect the association of HDAC6 with α-tubulin in the melanoma cells ([Supplementary Figure S5B](#S1){ref-type="supplementary-material"}).

If loss of CYLD was directly responsible for elevated HDAC6 activity and increased deacetylation of α-tubulin, siRNA-mediated depletion of HDAC6 in EGFP-expressing melanoma cells or *Cyld*^*−/−*^ keratinocytes should restore α-tubulin acetylation. In line with this hypothesis, the levels of acetylated α-tubulin increased in melanoma cells upon HDAC6 depletion ([Figure 5E](#f5){ref-type="fig"}). Furthermore, HDAC6-depleted *Cyld*^*−/−*^ keratinocytes showed significant increase in α-tubulin acetylation irrespective of whether they were untreated or treated with TPA ([Figure 5F](#f5){ref-type="fig"}).

Delay in the G~1~/S-phase of the cell cycle and cytokinesis induced by CYLD
---------------------------------------------------------------------------

To determine whether CYLD, through its effects on MTs, can regulate the duration of the cell cycle, we used serum starvation in combination with contact inhibition to arrest keratinocytes in G~1~-phase and nocodazole treatment to synchronize melanoma cells in G2/M-phase, and then analysed cell-cycle progression using flow cytometry ([Supplementary Figures S6](#S1){ref-type="supplementary-material"} and [7](#S1){ref-type="supplementary-material"}). The release of synchronized, TPA-treated keratinocytes caused a delay in G~1~-to-S phase transition in *Cyld*^*+/+*^ but not in *Cyld*^*−/−*^ keratinocytes ([Figure 6A](#f6){ref-type="fig"} and [Supplementary Figure S6](#S1){ref-type="supplementary-material"}). Similarly, release of synchronized, nocodazole-treated melanoma cells revealed a significant delay in G~1~-to-S phase progression and an accumulation in S-phase of EGFP--CYLD-expressing cells as compared with EGFP-expressing control cells ([Figure 6B](#f6){ref-type="fig"} and [Supplementary Figure S7](#S1){ref-type="supplementary-material"}). To further corroborate this finding, we performed BrdU pulse labelling of TPA-stimulated keratinocytes as well as melanoma cells. TPA-stimulated *Cyld*^*+/+*^ keratinocytes and EGFP--CYLD-expressing melanoma cells showed reduced levels of BrdU-positive nuclei as an indication of delayed S-phase progression in the presence of activated CYLD ([Figure 6C and D](#f6){ref-type="fig"}). To exclude the possibility that the delay in the G~1~/S-phase transition in CYLD-expressing cells is due to differences in mitosis, we quantified mitotic intervals by live-cell imaging. The experiments revealed that EGFP--CYLD-expressing melanoma cells and EGFP-expressing control cells displayed similar rates of mitosis ([Figure 6E](#f6){ref-type="fig"}).

We have reported earlier that CYLD decreases the proliferation of keratinocytes ([@b21]) and melanoma cells ([@b22]) by retaining Bcl-3 in the cytoplasm and thereby reducing the expression of cyclin-D1. Interestingly, depletion of Bcl-3 in EGFP-expressing or control melanoma cells increased the number of cells in G~1~-phase ([Figure 6F](#f6){ref-type="fig"}), while expression of CYLD^1--212^ or siRNA-mediated depletion of HDAC6 had no significant effect ([Figure 6F](#f6){ref-type="fig"}). To further assess whether the catalytic activity and/or HDAC6 and MT binding of CYLD are necessary to induce a delay in the cell cycle, we analysed the duration of the cell cycle in melanoma cells expressing full-length CYLD, catalytically inactive CYLD^C/S^, and a deletion mutant that lacks the first CAP-Gly domains (CYLD^222--956^) and does not bind HDAC6. Full-length CYLD induced a delay in G~1~/S transition, whereas the catalytically inactive CYLD^C/S^ or CYLD^222--956^ had no effect. Together, these results suggest that both deubiquitinase activity as well as HDAC6 binding are required for CYLD to regulate the cell cycle ([Figure 6G](#f6){ref-type="fig"}).

It has been suggested earlier that the localization of HDAC6 in the midbody might regulate mitosis by affecting MT dynamics during cytokinesis ([@b46]). This correlates with the notion that the cytoplasmic bridge connecting the two daughter cells contains high levels of acetylated MTs ([@b26]; [@b35]; [@b9]). We observed that CYLD localizes to the midbody during cytokinesis ([Figure 7A](#f7){ref-type="fig"}, upper panels). The localization of CYLD to the midbody has also previously been reported for dividing HeLa cells overexpressing CYLD ([@b38]). In addition, we observed that CYLD colocalized with HDAC6 in the midbody of both non-stimulated and TPA-stimulated primary *Cyld*^*+/+*^ keratinocytes ([Figure 7A](#f7){ref-type="fig"}, lower panels).

To analyse whether the observed localization of CYLD in the midbody could affect cytokinesis, we determined the duration of cytokinesis using live-cell imaging. The experiments revealed no differences in the duration of cytokinesis in non-stimulated *Cyld*^*+/+*^ and *Cyld*^*−/−*^ keratinocytes ([Figure 7B](#f7){ref-type="fig"}), while treatment of cells with TPA induced a significant delay in cytokinetic rate of *Cyld*^*+/+*^ as compared with that of *Cyld*^*−/−*^ keratinocytes ([Figure 7B](#f7){ref-type="fig"}). This phenotype could also be detected in EGFP--CYLD-expressing melanoma cells as compared with EGFP-expressing control cells ([Figure 7C](#f7){ref-type="fig"}). Furthermore, the N-terminal but not the C-terminal domain of CYLD localized to the midbody of melanoma cells ([Figure 7D](#f7){ref-type="fig"}) and induced a delay in cytokinesis ([Figure 7C](#f7){ref-type="fig"}). However, expressing CYLD^1--212^-carrying mutations in the CAP-Gly1 domain ([Supplementary Figure S2B](#S1){ref-type="supplementary-material"}), to disrupt MT binding ([@b12]), failed to induce a delay in cytokinesis, whereas the catalytically inactive mutant CYLD^C/S^ retained this ability ([Figure 7C](#f7){ref-type="fig"}). Altogether these results indicate that inhibition of Bcl-3 by the deubiquitinase activity of CYLD induces a delay in the G~1~/S transition, while the N-terminal domain of CYLD, which binds MTs and inhibits HDAC6 activity, regulates the perinuclear localization of CYLD and reduces the rate of cytokinesis.

Discussion
==========

CYLD is a deubiquitination enzyme, which acts primarily as a tumour-suppressor gene. Mutations in the *CYLD* gene were discovered in patients suffering from cylindromatosis, which is a benign tumour derived from the cells of the skin ([@b3]). We have recently shown that CYLD expression is very low in melanoma cells due to transcriptional suppression by high levels of Snail ([@b22]). Interestingly, gene mutation studies on cylindroma patients showed that the known mutations can cause either loss of expression or expression of C-terminally truncated versions of CYLD. The C-terminal part of CYLD harbours the UCH domain, which is responsible for the deubiquitinase activity of CYLD ([@b7]; [@b19]; [@b40]; [@b21]). So far, no cylindroma patients with mutations giving rise to N-terminal truncations of CYLD have been identified ([@b23]). It was speculated that this could be due to the ability of this region to delay tumour growth and thus be associated with lower disease penetrance. In the present study we investigated the role of the N-terminal CAP-Gly domains of CYLD in the growth and proliferation of both primary and transformed cells derived from the skin.

The N-terminal region of CYLD contains three CAP-Gly motifs. We found that two of them (CAP-Gly1 and CAP-Gly2) associated with tubulin and inhibited tubulin deacetylation. In addition, we found that TPA treatment of *Cyld*^*+/+*^ keratinocytes caused redistribution of CYLD and induced its accumulation in the perinuclear region, which has been previously shown to be critical in mediating the interaction with its downstream substrate Bcl-3 ([@b21]). In addition, TPA treatment lead to a marked increase in the levels of acetylated MTs in this area, and CYLD was found to extensively colocalize and associate with acetylated MTs. These observations suggest that CYLD colocalizes preferentially with acetylated MTs, and that the TPA-mediated increase of acetylated MTs in the perinuclear region might in fact regulate the translocation of CYLD to this area. This hypothesis is supported by the observation that inhibition of tubulin deacetylation by downregulation of HDAC6 or inhibition of its activity by TSA induced a similar translocation of CYLD to the perinuclear area where it colocalized with the abundant acetylated MTs, whereas depolymerisation of MTs inhibited the translocation.

HDAC6, which has been shown to operate as a α-tubulin-specific deacetylase ([@b17]), contains two intact catalytic domains in the central region of the protein. Mutations in the catalytic domains or treatment of cells with the HDAC6 inhibitor TSA abrogates the catalytic activity ([@b45]) and increases the pool of acetylated tubulin. Several lines of evidence suggest that CYLD regulates the levels of acetylated tubulin by acting as an endogenous inhibitor of HDAC6. First, inhibition of HDAC6 by TSA or tubacin treatment failed to induce an additive effect on acetylated tubulin in the presence of CYLD, suggesting that TSA, tubacin, and CYLD act within the same pathway. In addition, CYLD colocalized with HDAC6 in the perinuclear region, and the endogenous proteins were found in the same protein complex. Finally, we observed that CYLD binds to the catalytic domains of this enzyme and inhibits its tubulin deacetylase activity *in vitro*.

What are the functional consequences of CYLD-mediated inhibition of HDAC6 and the increased levels of acetylated MTs? We observed that CYLD induces a delay in the G~1~/S transition of the cell cycle, both in melanoma cells as well as in keratinocytes. This is in contrast to an earlier study where downregulation of CYLD by siRNA in HeLa cells induced a delay in G2/M transition of the cell cycle ([@b38]). This discrepancy could be explained by different functions of CYLD depending on the tissue/cell type in combination with the requirement of a specific stimulus such as TPA and/or by siRNA-mediated downregulation of CYLD versus complete absence of the protein. We have previously shown that CYLD, through deubiquitination of Bcl-3, prevents its nuclear translocation. This in turn inhibits the transcriptional activity of NF-κB p50/p52 and reduces the expression of cyclin-D1 ([@b21]). Since expression of cyclin-D1 is critical for the G~1~/S transition of the cell cycle, it is very likely that CYLD regulates the G~1~/S transition by inhibiting the expression of cyclin-D1. Interestingly, depletion of HDAC6 or expression of the N-terminal domain of CYLD, which interacts and inhibits HDAC6, was unable to increase the number of G~1~-phase cells, suggesting that the inactivation of HDAC6 and hyperacetylation of MTs alone is not the cause of the G~1~/S cell-cycle delay. This is supported by the finding that depletion of HDAC6 was not sufficient to induce the interaction of CYLD with Bcl-3, but TPA-mediated activation of CYLD is additionally required. However, a deletion mutant of CYLD, which is unable to bind HDAC6, but contains an intact catalytical domain, did not induce a delay in cytokinesis. Thus, we suggest that the association of CYLD with acetylated MTs leads to its perinuclear accumulation, which when followed by an additional TPA-mediated signal prevents nuclear accumulation of Bcl-3, leading to decreased cyclin-D1 expression and delay in G~1~/S transition. It is interesting to note that a direct interaction between HDAC6 and Bcl-3 has been reported earlier in other cell types ([@b42]), suggesting that formation of these protein complexes could be spatiotemporally linked.

The finding that CYLD colocalizes with HDAC6 in the midbody between bundles of acetylated MTs in both keratinocytes and melanoma cells, prompted us to investigate the rate of cytokinesis in these cells. Although CYLD is present in the midbody of primary keratinocytes both before and after TPA treatment, CYLD was found to induce a delay in cytokinesis only after TPA treatment. We could also detect a reduction in the rate of cytokinesis in melanoma cells expressing EGFP--CYLD, and in line with the effect of EGFP--CYLD on G~1~/S-phase transition of melanoma cells, also this effect did not require an additional stimulus. Interestingly, the N-terminal domain, which binds to tubulin and HDAC6, but not the UCH-containing C-terminal domain of CYLD, was able to localize to the midbody and induce a delay in cytokinesis. In addition, mutations in the CAP-Gly1 domain, which impair MT binding, abolished this effect, whereas a catalytically inactive CYLD had no effect. This suggests that localization of CYLD to the midbody is important for its effect on cytokinesis, whereas deubiquitinase activity of CYLD is not required for this function. The reason why CYLD does not have an effect on cytokinesis in the absence of TPA treatment in the primary keratinocytes, despite its presence in the midbody, is unclear. It is possible that TPA induces additional changes in CYLD itself or in unidentified inhibitory proteins, which are necessary for the function of CYLD. This hypothesis is supported by our finding that CYLD is unable to bind HDAC6 in the absence of TPA treatment. The molecular details of this process need to be addressed in future studies.

The precise role of acetylated MTs and tubulin acetylation in the regulation of the cell cycle and mitosis is not understood, although it is known that the cytoplasmic bridge connecting the two daughter cells during cytokinesis is highly enriched in acetylated tubulin in many cell types ([@b26]; [@b35]; [@b9]). Previous studies have shown that the degree of tubulin acetylation reflects the dynamics of MTs (reviewed by [@b44]), and that stable, nocodazole-resistant MTs are essential for recruitment of myosin-II and RhoA to allow contraction of the cleavage furrow during cytokinesis ([@b2]). In addition, tubulin acetylation itself regulates the recruitment and dynamics of the MT motor protein kinesin-1, which regulates long-distance intracellular delivery ([@b29]). Interestingly, HDAC6-mediated tubulin acetylation was recently shown to regulate intracellular transport in neurons ([@b11]). It is, therefore, possible that CYLD, through its effect on HDAC6 or a direct effect on the MTs, regulates the dynamics of MTs and/or recruitment of proteins required for successful execution of cytokinesis. Interestingly, other tumour suppressors have previously been shown to use tubulin acetylation as mechanism to regulate the cell cycle. Loss of the tumour suppressor LAPSER1, which also localizes to the midbody, leads to a decrease in acetylated tubulin accompanied by an increase in the rate of cytokinesis and proliferation ([@b39]). The tumour suppressor CHFR also localizes to the midbody and regulates the levels of acetylated α-tubulin in the mitotic spindle during cytokinesis ([@b27]).

Taken together, CYLD simultaneously employs two functional properties to negatively regulate the proliferation rates of keratinocytes and melanoma cells. The abnormal cell-cycle progression through G~1~ phases and cytokinesis are both hallmarks of cancer cell proliferation. Since many tumour types and cancer cell lines lack or have low CYLD expression ([@b15]; [@b22]), our findings provide a mechanistic explanation for their elevated proliferation rates.

Materials and methods
=====================

Cell culture and transfection
-----------------------------

The melanoma cell lines Mel Im and Mel Juso were derived from metastases of malignant melanomas ([@b33]). Isolation and culture of primary normal human epidermal melanocytes (NHEM) were performed as previously described by [@b33]. Primary keratinocytes were isolated from back skin of 8-week-old mice and cultured as described by [@b32].

Viral infections
----------------

Stable expression of EGFP, EGFP--CYLD, HA--CYLD, and HA--CYLD^C/S^ in melanoma cells was achieved by lentiviral gene transfer. In brief, CMV promoter-driven lentiviral constructs were obtained by cloning EGFP, EGFP--CYLD, HA--CYLD, and HA--CYLD^C/S^ into a lentiviral vector (p156rrlsinPPTCMV). The titre of the lentiviral particles was determined by measuring the amount of HIV p24 gag antigen by ELISA (Alliance; NEN). To calculate the amount of infectious units (IU), the p24 titre was correlated to the biological activity of a similar virus carrying a green-fluorescent protein (GFP) cassette by using serial dilutions of the GFP virus to transduce 293T cells (1 ng of p24=1 × 10^5^ IU). Melanoma cells were infected with 1 × 10^5^ IU for 24 h using the calcium phosphate method and the medium was replaced two times before the cells were used in different assays.

Transient transfections
-----------------------

CYLD truncation mutants were amplified by PCR and cloned into CMV promoter-driven pCS2 construct. The CAP-Gly1 mutant was generated by mutating the GFTDG sequence in the CYLD^1--212^ construct into AFADA, Transient transfection assays were performed in six-well plates at 80% confluence using the Polyfect transfection reagent (Qiagen) and 1.0 or 3.0 μg of DNA, and 10 or 30 μl of Polyfect were suspended in cell growth medium containing no serum or antibiotics. The mixture was incubated for 10 min at room temperature to allow complex formation. Cells were washed once with phosphate-buffered saline (PBS) before adding 1 ml of fresh cell growth medium containing serum and antibiotics, after which the transfection mixture was added to the cells. Experiments were performed 24 or 48 h after transfection. All transfection assays were repeated three times and performed in triplicates.

Depletion of Bcl-3 and HDAC6
----------------------------

SiRNAs (control, Bcl-3, and HDAC6) were purchased from Santa Cruz. SiRNA duplexes (0.2 μM) were mixed with Lipofectamine (Invitrogen) transfection reagent (10 μl) and incubated at room temperature for 15 min. For each transfection, 0.8 ml siRNA transfection mixture was added to 80% confluent cells in six-well tissue culture plate two times within 24 h. Experiments were performed 24 h after transfection.

Immunoblots and immunoprecipitation
-----------------------------------

For immunobloting, lysates from whole cells or cytosolic and nuclear extracts were resolved in SDS±PAGE gels and transferred to PVDF membranes, followed by incubation with primary antibodies anti-total α-tubulin; anti-tyrosinated α-tubulin; anti-acetylated α-tubulin; anti HA and α-FLAG M2 agarose beads (all from Sigma); anti-rat monoclonal tubulin (from Abcam); anti-HDAC6; anti-lamin-B and anti-Bcl-3 (from Santa Cruz). Rabbit polyclonal Cyld antibody has been described earlier ([@b21]).

For immunoprecipitations lysates were obtained from untreated or TPA-treated (100 nM) primary keratinocytes, human primary melanocytes (NHEM), or human malignant melanoma cell lines. The samples were centrifuged at 10 000 *g* for 20 min. For anti-CYLD immunoprecipitation the lysates were pre-cleared for 30 min at 4°C. The protein content was determined and compensated for equal content in all supernatants and used for immunoprecipitation. FLAG immunoprecipitation was performed by using anti-FLAG M2 affinity gel and eluted using FLAG-peptide purchased from Sigma. HA immunoprecipitation was performed by using anti-HA antibody and eluted using HA-peptide purchased from Sigma. EGFP immunoprecipitation was performed by using anti-GFP microBeads purchased from Miltenyi Biotech and used according to the manufacturer\'s instructions. Immunoblots were developed with the ECL-plus reagent (Amersham Biosciences) according to the manufacturer\'s instructions.

Immunofluorescence
------------------

Cells were grown on glass coverslips and fixed with ice-cold 100% methanol. After rehydration with PBS, unspecific binding was blocked with PBS containing 3% bovine serum albumin (BSA) and 5% goat serum, followed by incubation with primary antibodies against CYLD ([@b21]), tyrosinated tubulin (Chemicon), FLAG (Sigma), acetylated tubulin (Sigma), and HDAC6 (Santa Cruz), and fluorescence labelled secondary antibodies (Alexa, Invitrogen). Finally, the coverslips were washed and mounted on glass slides using Vectashield (Vector Laboratories). The fluorescence images were collected by laser-scanning confocal microscopy (DMIRE2; Leica) using Leica Confocal Software version 2.5 Build 1227 with × 100 oil-immersion objectives. All images were collected at room temperature.

Colocalization was measured by linescans from immunofluorescence images using the MetaMorph software.

*In vitro* tubulin deacetylation assay
--------------------------------------

Tubulin deacetylation assays were performed as described earlier ([@b17]). Briefly, MAP-enriched bovine tubulin (cytoskeleton) was polymerised into microtubules in the absence of paclitaxel or glycerol by incubation for 30 min at 35°C. The polymerised microtubules were incubated at 37°C for 2 h with HA--HDAC6 and/or FLAG--CYLD immunoprecipitates (after elution using HA respective FLAG peptide; Sigma) in the absence or presence of TSA (0.5 μM). Samples were then placed on ice for 15 min. The supernatant was subsequently collected by centrifugation and analysed by immunoblotting with antibodies against acetylated tubulin and total tubulin.

Flow cytometry and BrdU labelling
---------------------------------

Malignant melanoma cells were synchronized by treatment with 100 ng/ml nocodazole for 16 h. Primary keratinocytes were synchronized by a combination of contact inhibition and serum starvation for 24 h, after which they were released into complete growth medium containing 1 μM TPA. After release the cells were harvested at the indicated time points and fixed with 70% ethanol. Cells were then stained with propidium iodide and analysed by flow cytometry (FACSCalibur, Becton Dickinson, Franklin Lakes, NY, USA) using FlowJo software (Tree Star Inc., Ashland, OR, USA).

BrdU pulse labelling was performed by arresting cells as described above. After release, the cells were exposed to BrdU (10 μM) for 12 or 24 h. The cells were then fixed with 4% paraformaldehyde and subsequently with 100% methanol. DNA was denatured using 1.5 M HCl and BrdU labelling was detected using anti-BrdU antibodies (Sigma) and fluorescent secondary antibodies.

Quantification of mitotic phases and cytokinesis
------------------------------------------------

Malignant melanoma cells were plated on plastic culture dishes and synchronized using a double thymidine block. Briefly, cells were treated with 2 mM thymidine for 19 h. After a 5-h release in complete culture medium, the cells were treated with thymidine for another 16 h. After release, images of live cells were recorded with a Zeiss Axiovert 200M (Zeiss, Germany) with a cooled CCD camera (Roper Scientific, Princeton, NJ, USA). Image acquisition was performed with the MetaMorph software (Molecular Devices, Downington, PA, USA). For quantification of mitotic intervals, the duration of mitotic phases were defined as follows: prometaphase, from disassembly of nuclear membrane and nucleoli to equatorial arrangement of chromatin; metaphase, from the beginning to the end of equatorial arrangement of chromatin; anaphase, from the start of sister chromatid separation to reformation of nuclear envelopes and nucleoli; telophase, from the start of nuclear envelope and nucleolar reformation to formation of two daughter cells.

For quantification of cytokinesis cells were plated on plastic culture dishes in complete culture medium and stimulated with 100 nM TPA, when indicated. Images of live cells were recorded as described above. The duration of cytokinesis was quantified from the formation of two daughter cells to abscission.

Statistical analysis
--------------------

Data are presented as mean±s.e.m. Statistical comparisons were assessed with analysis of variance (ANOVA) or Student\'s *t*-test after data were confirmed to fulfil the criteria of normal distribution and equal variance. If overall ANOVA tests were significant, we performed a *post hoc* Tukey test. *P*\<0.05 was considered significant.
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![Interaction of CYLD with tubulin and microtubules. (**A**) The confocal plane of keratinocytes stained for acetylated α-tubulin and CYLD in the absence or presence of 100 nM TPA for 30 min. The fluorescence intensity linescan profile was generated through the merged image and demonstrates the dependence of the two fluorescent populations. (**B**) Immunoprecipitation of endogenous CYLD (left panels), α-tubulin (right panels), or control antibody (IgG) from human primary melanocytes, and immunoblotting against α-tubulin or CYLD. The lysate shows equal amount of protein used for immunoprecipitation. (**C**) Immunoprecipitation of α-tubulin from primary mouse keratinocytes in the absence or presence of nocodazole (10 μM for 60 min), and immunoblotting against α-tubulin, CYLD, or MAP4. The lysate (lower panel) shows equal amount of protein used for immunoprecipitation. (**D**) Immunoprecipitation of endogenous CYLD from human melanocytes in the absence or presence of nocodazole (10 or 30 μM for 60 min), and immunoblotting against α-tubulin or CYLD. The lysate (lower panel) shows equal amount of protein used for immunoprecipitation. (**E**) Microtubule co-sedimentation assay using *in vitro* translated, ^35^S-labelled CYLD (upper panel) or Bax (lower panel) in the presence or absence of taxol-stabilized microtubules. S: Supernatant and P: Pellet fraction of samples separated with SDS--PAGE after which the presence of ^35^S-labelled CYLD or Bax was detected by fluorography. (**F**) FLAG immunoprecipitates of HeLa cells transiently transfected with different FLAG-tagged deletion mutants of CYLD (1.0 μg) and analysed by immunoblotting with antibodies against α-tubulin.](emboj2009317f1){#f1}

![CYLD increases the level of acetylated α-tubulin. (**A**) Analysis of the levels (left panels) and quantification (right panel) of acetylated α-tubulin and total tubulin in *Cyld*^*+/+*^ and *Cyld*^*−/−*^ keratinocytes treated with TPA (15, 30 and 60 min). (**B**) Immunoprecipitation of endogenous CYLD from keratinocytes treated with 100 nM TPA and immunoblotting against acetylated-α-tubulin or CYLD. The lysate (lower panel) shows equal amount of protein used for immunoprecipitation. (**C**) Analysis of the levels of acetylated α-tubulin and total tubulin in untreated or TPA-treated (30 min) *Cyld*^*−/−*^ keratinocytes (control) or *Cyld*^*−/−*^ keratinocytes transiently transfected with full-length-CYLD for 48 h. (**D**) Analysis of the levels of acetylated α-tubulin, total tubulin, or CYLD in two different melanoma cell lines (MEL Im and Juso) infected with mock, EGFP, or EGFP--CYLD lentivirus (1 × 10^5^ IU) for 24 h. The medium was replaced two times before the cells were lysed and used for immunoblotting against α-tubulin, total tubulin, or CYLD. (**E**) Analysis of the levels of acetylated α-tubulin, total tubulin, and CYLD in melanoma cells (Juso) transiently transfected with increasing concentrations of EGFP--CYLD cDNA. (**F**) The confocal plane of human malignant melanoma cell line (Juso) transiently transfected with 1.0 μg EGFP--CYLD (green) for 24 h and stained for acetylated α-tubulin (red). The asterisk indicates cells lacking CYLD expression. (**G**) Analysis of the levels of acetylated α-tubulin and total tubulin in melanoma cells transduced with 1 × 10^5^ IU of HA, HA--CYLD, or the catalytically inactive mutant HA--CYLD^C/S^ lentivirus for 24 h. The medium was replaced two times before the cells were lysed and used for immunoblotting against α-tubulin, total tubulin, or CYLD. (**H**) Immunofluorescence staining of microtubule re-growth of EGFP and EGFP--CYLD lentivirus-infected melanoma cells after treatment with nocodazole (50 μM) for 10 min, followed by a washout and incubation in fresh culture medium at 37°C for 10, 30, or 120 min. (**I**) EGFP or EGFP--CYLD lentivirus-infected melanoma cells were used to analyse the levels of acetylated α-tubulin and total tubulin in untreated cells or cells treated with nocodazole (50 μM) for 10 min followed by a washout and incubation in fresh culture medium at 37°C for 10, 30, or 120 min before cell lysis. ^\*^*P*\<0.05.](emboj2009317f2){#f2}

![CYLD inhibits the activity of HDAC6 and tubulin deacetylation. (**A**) Analysis of the levels (left panels) and quantification (right panel) of acetylated α-tubulin and total tubulin in *Cyld*^*+/+*^ and *Cyld*^*−/−*^ keratinocytes treated with 1 mM sodium butyrate (4 h) before stimulation with 100 nM TPA (30 min). (**B**) Analysis of the levels (left panels) and quantification (right panel) of acetylated α-tubulin and total tubulin in *Cyld*^*+/+*^ and *Cyld*^*−/−*^ keratinocytes treated with 0.3 μM TSA (60 min) before stimulation with 100 nM TPA (30 min). (**C**) Analysis of the levels of acetylated α-tubulin and total tubulin in *Cyld*^*+/+*^ and *Cyld*^*−/−*^ keratinocytes treated with 2 μM tubacin (4 h) before stimulation with 100 nM TPA (30 min). (**D**) Analysis of the levels (left panels) and quantification (right panel) of acetylated α-tubulin and total tubulin in untreated or TSA (0.3 or 5 μM for 60 min)-treated, EGFP or EGFP--CYLD lentivirus-infected melanoma cells. (**E**) Analysis of the levels of acetylated α-tubulin and total tubulin in untreated or tubacin (2 μM for 4 h)-treated, EGFP or EGFP--CYLD lentivirus-infected melanoma cells. (**F**) The confocal plane of primary mouse keratinocytes untreated or treated with 0.3 μM TSA (15 min) and stained for acetylated α-tubulin (red) and CYLD (green). (**G**) Untreated, TPA- (100 nM for 30 min), nocodazole- (10 μM for 60 min), or TSA (0.3 μM for 60 min)-treated *Cyld*^*+/+*^ keratinocytes immunoprecipitated with antibodies against Bcl-3 and immunoblotted against CYLD. The lysate (lower panel) shows equal amount of protein used for immunoprecipitation. (**H**) *Cyld*^*+/+*^ keratinocytes were transiently transfected with control or HDAC6 siRNA (24 h) in the absence or presence of TPA (100 nM for 30 min), followed by immunoprecipitation of endogenous Bcl-3 and immunoblotting against CYLD. The lysate shows equal amount of protein used for immunoprecipitation and knockdown efficiency of HDAC6. ^\*^*P*\<0.05.](emboj2009317f3){#f3}

![Interaction of CYLD with HDAC6. (**A**) Cytoplasmic and nuclear extracts of keratinocytes (*Cyld*^*+/+*^ and *Cyld*^*−/−*^) in the presence or absence of TPA (100 nM for 30 min), immunoblotted with antibodies against HDAC6, lamin-B, and tubulin. (**B**) Immunoprecipitation of CYLD and immunoblotting against HDAC6 and CYLD untreated, TPA- (100 nM for 30 min) and/or nocodazole (10 μM for 60 min)-treated *Cyld*^*+/+*^ keratinocytes. The lysate (lower panel) shows equal amount of protein used for immunoprecipitation. (**C**) The confocal plane of *Cyld*^*+/+*^ keratinocytes stimulated for 30 min with 100 nM TPA and stained for HDAC6 (red) and CYLD (green). (**D**) HeLa cells were transiently transfected with FLAG-tagged, wild-type or different deletion mutants of CYLD, incubated for 24 h, lysed, immunoprecipitated using α-FLAG M2 agarose beads, and immunoblotted against endogenous HDAC6 or FLAG. The lysate (lower panel) shows equal amount of protein used for immunoprecipitation. (**E**) HeLa cells were transiently transfected with HA-tagged, full-length or different deletion mutants of HDAC6 and FLAG-tagged, full-length CYLD. After transfection (24 h) the cells were lysed, immunoprecipitated using α-FLAG M2 agarose beads, and immunoblotted against HA or FLAG. The lysate (lower panel) shows equal amount of protein used for immunoprecipitation. (**F**) His-tagged CYLD was purified from COS cells transiently transfected with His--CYLD (1.0 μg for 48 h) and incubated with recombinant N-terminal GST--HDAC6 for 30 min followed by precipitation of His-tagged protein complexes using Ni--NTA agarose beads. The bound proteins were recovered from the beads and analysed by immunoblotting against GST to detect GST--HDAC6 or His to detect His--CYLD. (**G**) Purified GST or GST--CYLD^1--212^ protein was incubated with His--HDAC6 *in vitro* for 30 min followed by GST pull down using glutathione--agarose beads. The complex was recovered from the beads and analysed by immunoblotting against His to detect His--HDAC6 or GST to detect GST--CYLD^1--212^.](emboj2009317f4){#f4}

![The N-terminal domain of CYLD is responsible for inhibition of HDAC6 activity. (**A**) MAP-enriched bovine tubulin (cytoskeleton) was polymerised into microtubules in the absence of taxol or glycerol by incubation for 30 min at 35°C. The polymerised microtubules were incubated with endogenous HDAC6 and/or EGFP--CYLD immunoprecipitates from melanoma cells in the absence or presence of TSA (0.5 μM) at 37°C for 2 h. Samples were placed on ice for 15 min and the supernatant was collected by centrifugation and analysed by immunoblotting. (**B**) COS cells were transiently transfected with different concentrations of FLAG--CYLD (0.5, 1.0 and 3.0 μg) or HA--HDAC6 (1.0 μg) for 24 h. Polymerised microtubules were incubated with CYLD and/or HDAC6 eluted from the corresponding immunoprecipitates at 37°C for 2 h. Samples were placed on ice for 15 min and the supernatant was collected by centrifugation and analysed by immunoblotting. (**C**) COS cells were transiently transfected with FLAG-tagged, wild-type or truncation mutants of CYLD or HA-tagged HDAC6 constructs (1.0 μg of each for 24 h). Polymerised microtubules were then incubated with CYLD and/or HDAC6 eluted from the corresponding immunoprecipitates at 37°C for 2 h. Samples were placed on ice for 15 min and the supernatant was collected by centrifugation and analysed by immunoblotting. (**D**) Immunoprecipitation of endogenous HDAC6 from *Cyld*^*+/+*^ and *Cyld*^*−/−*^ keratinocytes in the absence or presence of TPA (100 nM for 30 min) and immunoblotting against tubulin and HDAC6 in the absence or presence of TPA (100 nM for 30 min). The lysate (lower panel) shows equal amount of protein used for immunoprecipitation. (**E**) Immunoblot analysis of HDAC6, acetylated α-tubulin, and total tubulin in EGFP- or EGFP--CYLD-expressing melanoma cells before or after 24 h of transient transfection with HDAC6 siRNAs (0.2 μM). (**F**) Immunoblot analysis of HDAC6, acetylated α-tubulin, and total tubulin in untreated or TPA (100 nM for 30 min)-treated *Cyld*^*−/−*^ keratinocytes before or after transient transfection with HDAC6 siRNAs.](emboj2009317f5){#f5}

![CYLD induces a delay in the G1/S phase of the cell cycle. (**A**) Cell-cycle distribution of *Cyld*^*+/+*^ and *Cyld*^*−/−*^ keratinocytes after synchronization by serum starvation and contact inhibition for 24 h and stimulation with 100 nM TPA for 24 h. (**B**) Cell-cycle distribution of EGFP or EGFP--CYLD-infected melanoma cells 16 h after synchronization with 30 μM nocodazole. (**C**) BrdU pulse labelling of keratinocytes synchronized by serum starvation and contact inhibition followed by BrdU exposure (10 μM) for 12 or 24 h after the release. (**D**) BrdU pulse labelling of EGFP and EGFP--CYLD lentivirus-infected melanoma cells after arrest with with nocodazole (30 μM for 16 h) and exposure to BrdU (10 μM) for 12 or 24 h after the release. (**E**) Duration of mitosis in EGFP- or EGFP--CYLD-infected melanoma cells after synchronization by a double thymidine (2 mM) block. (**F**) The G~1~ cell-cycle phase of melanoma cells transiently transfected with EGFP (control), CYLD^1--212^, or/and Bcl-3 or HDAC6 siRNA and synchronized with nocodazole. (**G**) The G~1~ cell-cycle phase of melanoma cells transiently transfected with mock (control), CYLD, CYLD^C/S^, or CYLD^222--956^ and synchronized with nocodazole. ^\*^*P*\<0.05, ^\*\*^*P*\<0.01, ^\*\*\*^*P*\<0.001.](emboj2009317f6){#f6}

![The N-terminal part of CYLD induces a delay in the cytokinesis rate. (**A**) The confocal plane of keratinocytes stained for acetylated α-tubulin, CYLD, or HDAC6 as indicated. The arrows indicate the localization of CYLD and HDAC6 in the midbody. (**B**) Duration of cytokinesis of *Cyld*^*+/+*^ and *Cyld*^*−/−*^ cells after TPA (100 nM) treatment. (**C**) Duration of cytokinesis in melanoma cells (Juso) transiently transfected with mock (control), CYLD, CYLD^1--212^, CYLD^587--956^, CYLD^C/S^, or CYLD^1--212^--CAP1-Gly mutant. (**D**) The confocal plane of melanoma (Juso) transfected with expression vectors FLAG-CYLD^1--212^, or FLAG--CYLD^587--956^ and stained for acetylated α-tubulin and FLAG. The arrow indicates the localization of CYLD^1--212^ in the midbody. ^\*\*^*P*\<0.01.](emboj2009317f7){#f7}
